The present invention describes the use of pharmaceutical compounds in pharmaceutical compositions for sublingual administration including as active ingredient thereof an agonist of the central receptor of benzodiazepinics chosen among diazepam lorazepam bromazepam triazolam alprazolam flunitrazepam nitrazepam and midazolam maleate in a mixture with a pharmaceutical excipient consisting of at least 70% of the weight of the final formulation containing 40-45% by weight of lactose 15-27% by weight...

Una composición farmacéutica sublingual que comprende 0125-10% en peso de un agonista del receptor benzodiazepínico central seleccionado entre el grupo constituido por maleato de midazolam diazepam lorazepam bromazepam triazolam alprazolam flunitrazepam y nitrazepam y conteniendo al menos el 70% en peso de la formulación final la siguiente mezcla ternaria i) 40-45% de lactosa ii) 15-27% de sorbitol y iii) 12-16% de celulosa.

FIELD medicine. ^ SUBSTANCE invention suggests pharmaceutical compositions intended for sublingual intake as active ingredient of which agonist of central receptor of benzodiazepines is used selected from the following list diazepam lorazepam bromazepam triazolam alprazolam flunitrazepam nitrazepam midazolam-maleate in mixture with pharmaceutical excipient which constitutes at least 70% of total weight of ready composition and which contains lactose in amount from 40 to 45 wt % corbite in amount...

The present invention describes the use of pharmaceutical compounds in pharmaceutical compositions for sublingual administration including as active ingredient thereof an agonist of the central receptor of benzodiazepinics chosen among diazepam lorazepam bromazepam triazolam alprazolam flunitrazepam nitrazepam and midazolam maleate in a mixture with a pharmaceutical excipient consisting of at least 70% of the weight of the final formulation containing 40-45% by weight of lactose 15-27% by weight...

The present invention describes the use of pharmaceutical compounds in pharmaceutical compositions for sublingual administration including as active ingredient thereof an agonist of the central receptor of benzodiazepinics chosen among diazepam lorazepam bromazepam triazolam alprazolam flunitrazepam nitrazepam and midazolam maleate in a mixture with a pharmaceutical excipient consisting of at least 70% of the weight of the final formulation containing 40 - 45% by weight of lactose 15- 27% by wei...

\COMPOSIçãO FARMACêUTICA A BASE DE UM AGONISTA DO RECEPTOR CENTRAL DE BENZODIAZEPìNICOS\". A presente invenção descreve o uso de compostos farmacêuticos em composições farmacêuticas para administração sublingual incluindo como princípio ativo dos mesmos um agonista do receptor central dos benzodiazepínicos escolhido entre diazepam lorazepam bromazepam triazolam alprazolam flunitrazepam nitrazepam e maleato de midazolam em mistura com um excipiente farmac...

The present invention describes the use of pharmaceutical compounds in pharmaceutical compositions for sublingual administration including as active ingredient thereof an agonist of the central receptor of benzodiazepinics chosen among diazepam lorazepam bromazepam triazolam alprazolam flunitrazepam nitrazepam and midazolam maleate in a mixture with a pharmaceutical excipient consisting of at least 70% of the weight of the final formulation containing 40 - 45% by weight of lactose 15- 27% by wei...

1. A water-soluble pharmaceutical product in a solid state and true aqueous solutions of said product comprising a) a therapeutically active substance having a low aqueous solubility of less than 1x10 moles/litre and having a high binding affinity to a plasma protein - wherein the term "high binding affinity" means that more than 90% of the active substance is bound to the applied plasma protein in an aqueous medium in spontaneous equilibrium and room temperature; b) a plasma protein fraction in...